1030613-36-5

Basic information

• Product Name: 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide
• Synonyms: 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide
• CAS NO: 1030613-36-5
• Molecular Weight: 384.205
• Mol File: 1030613-36-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide(1030613-36-5)
• EPA Substance Registry System: 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide(1030613-36-5)

Safety Data

• Hazardous Substances Data: 1030613-36-5(Hazardous Substances Data)

Upstream product

• 916971-27-2 4-(2-bromo-5-fluorophenoxy)piperidine 
• 1313515-96-6 ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 147460-41-1 2-bromo-5-fluorophenol 
• 348-57-2 2,4-difluorobromobenzene 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 1030613-34-3 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-4,5-dihydroisoxazole-5-carboxylic acid amide 

Downstream Products

• 1030613-38-7 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carbonitrile 
• 1030613-40-1 4-(2-bromo-5-fluorophenoxy)-1-[5-(1H-tetrazol-5-yl)isoxazol-3-yl]-piperidine 
• 1030613-41-2 ethyl (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazol-5-yl}-2H-tetrazol-2-yl)acetate 
• 1030613-72-9 ethyl (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazol-5-yl}-1H-tetrazol-1-yl)acetate 
• 1030612-90-8 2-(5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl}-2H-1,2,3,4-tetrazol-2-yl)acetic acid 
• 1313515-97-7 2-(5-{3-[4-(2-bromo-5-fluorophenoxv)piperidin-l-yl]isoxazol-5-y1}-2H-tetrazol-2-yl)(2-⁽¹⁴⁾C)acetic acid 
• 1030613-40-1 4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)isoxazol-3-yl]piperidine 
• 1329632-66-7 (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-isoxazol-5-yl}tetrazol-2-yl)-acetic acid tert-butyl ester 

Relevant articles and documents

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia

The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.